Juhani Saarinen

Company: Glykos Finland Oy

Job title: Chief Executive Officer


Novel MMAU Auristatin Glycoside ADC Against Melanoma – Stabilised Hydrophilic Linker-Payload Provides A Wide Therapeutic Window & Improved Potency 10:30 am

Review novel auristatin ADCs based on MMAU payload enable widening of therapeutic window compared to vedotin ADCs Discuss how high systemic and metabolic stability of cleavable glycopeptide linker improved both in vivo efficacy and tolerability Assess DAR4 and DAR8 MMAU ADCs against solid and heme malignanciesRead more

day: Conference Day Two

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.